Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke

BACKGROUND: The cardiovascular safety and efficacy of linagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus (T2DM) after acute coronary syndrome (ACS) or acute ischemic stroke (AIS) are unclear. The aim of our real-world cohort study was to evaluate the cardiovas...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cardiovasc Diabetol
Asıl Yazarlar: Li, Yan-Rong, Tsai, Sung-Sheng, Chen, Dong-Yi, Chen, Szu-Tah, Sun, Jui-Hung, Chang, Hung-Yu, Liou, Miaw-Jene, Chen, Tien-Hsing
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2018
Konular:
Original Investigation
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5753457/
https://ncbi.nlm.nih.gov/pubmed/29301579
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-017-0655-y
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller